Barclays PLC Invests $298,000 in Clover Health Investments, Corp. (NASDAQ:CLOV)

Barclays PLC bought a new stake in Clover Health Investments, Corp. (NASDAQ:CLOV - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 105,766 shares of the company's stock, valued at approximately $298,000.

Other institutional investors also recently bought and sold shares of the company. Concurrent Investment Advisors LLC acquired a new position in shares of Clover Health Investments during the third quarter worth about $28,000. Sigma Planning Corp acquired a new position in shares of Clover Health Investments during the third quarter worth about $29,000. Parallax Volatility Advisers L.P. acquired a new position in shares of Clover Health Investments during the third quarter worth about $38,000. Realta Investment Advisors acquired a new position in Clover Health Investments in the third quarter valued at approximately $44,000. Finally, Forum Financial Management LP boosted its holdings in Clover Health Investments by 33.8% in the third quarter. Forum Financial Management LP now owns 16,077 shares of the company's stock valued at $45,000 after purchasing an additional 4,061 shares in the last quarter. 19.77% of the stock is owned by institutional investors and hedge funds.

Clover Health Investments Stock Performance

NASDAQ CLOV traded up $0.16 on Tuesday, reaching $4.24. The stock had a trading volume of 6,721,023 shares, compared to its average volume of 6,691,404. Clover Health Investments, Corp. has a 12-month low of $0.61 and a 12-month high of $4.71. The business's 50-day moving average price is $3.37 and its 200 day moving average price is $3.04. The stock has a market cap of $2.12 billion, a P/E ratio of -21.20 and a beta of 1.95.

Clover Health Investments (NASDAQ:CLOV - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.01. Clover Health Investments had a negative return on equity of 25.46% and a negative net margin of 5.92%. The company had revenue of $330.99 million during the quarter, compared to analysts' expectations of $347.60 million. During the same quarter in the previous year, the business earned ($0.09) earnings per share. On average, sell-side analysts predict that Clover Health Investments, Corp. will post -0.12 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. UBS Group assumed coverage on Clover Health Investments in a report on Monday, October 7th. They issued a "neutral" rating and a $4.00 price target for the company. Craig Hallum assumed coverage on Clover Health Investments in a report on Tuesday, December 17th. They issued a "buy" rating and a $6.00 price target for the company.

Clover Health Investments Company Profile

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.